Saccharomyces cerevisiae변이주 세포벽 유래의 베타글루칸의 면역활성 및 Cisplatin과의 병용에 의한 항암 상승작용 = Immunostimulating Activity of Beta-Glucan Isolated from the Cell Wall of Mutant Saccharomyces cerevisiae, and Its Anti-Tumor Application in Combination with Cisplatin

다국어 초록 (Multilingual Abstract)

Cisplatin(cis-diamminedichloroplatium) is one of the most effective anti-cancer drugs being clinically used in the treatment of solid tumors. Despite its therapeutic benefits, its use in clinical practice is often limited because of dose related toxicity.
It is known that yeast cell wall beta-glucans possess immuno-modulating properties, which allows for their application in antitumor therapy. IS2 is a kind of beta-glucan derived from the cell wall of mutated Saccharomyces cerevisiae, which exhibits anti-cancer activity in vitro and in vivo. The present study explored the possibility of combination therapy of IS2with cisplatin. In experimental metastasis of colon26-M3.1 cells, prophylactic intravenous administration of IS-2 in combination with cisplatin effectively inhibited tumor metastasis compared with cisplatin alone or IS-2 treatment in vivo. IS-2 effectively enhanced Th1 type cytokines including IFN-γ, IL-2, IL-12 and GM-CSF. Simultaneously, this combined treatment inhibited production of Th2 type cytokines compared with control. These results suggested that IS-2 can be applied in combination therapy with anti-cancer drugs to minimize their side effects

참고문헌 (Reference)

1 박정훈, "효모변이주 Saccharomyces cerevisiae IS2 세포벽 유래의 베타글루칸 면역활성능에 관한 연구" 한국식품과학회 35 (35): 488-492, 2003

2 정재혁, "桑白皮의 선천면역 활성화에 의한 항암 효과" 대한한방부인과학회 22 (22): 31-40, 2009

3 Kogan G, "Yeast cell wall polysaccharides as antioxidants and antimutagens: Can they fight cancer?" 55 : 387-393, 2008

4 Romagnani S, "Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease" 21 : 152-158, 1991

5 Chan GCF, "The effect of β-glucan on human immune and cancer cells" 2 : 1-11, 2009

6 Wang SY, "The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes" 70 : 699-705, 1997

7 Kovacs E, "Serum level IL-12 and the production of IFNgamma, IL-2 and IL-4 by peripheral blood mononuclear cell (PBMC) in cancer patients treated with Ciscum albun extract" 54 : 305-310, 2000

8 Kelly G, "Process for glucan preparation and therapeutic uses of glucan. US Patent 6,242,594"

9 Carlton BC, "Manual of Methods for General Bacteriology" American Society for Microbiology 222-242, 1981

10 Masuda Y, "Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice" 9 : 620-626, 2009

11 Dauphinée MJ, "Interleukin 2 deficiency is a common feature of autoimmune mice" 127 : 2483-2487, 1981

12 Hee Sun Song, "In Vitro Antioxidant Activity Profiles of β-Glucans Isolated from YeastSaccharomyces cerevisiae and Mutant Saccharomyces cerevisiae IS2" 한국식품과학회 15 (15): 437-440, 2006

13 Fiorentino DF, "IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells" 146 : 3444-3451, 1991

14 Urosevic M, "HLA-G and IL-10 expression in human cancer-different stories with the same message" 13 : 337-342, 2003

15 Westermann J, "Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study" 49 : 613-620, 2001

16 Ko JC, "Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2" Lung Cancer in press 2009

17 Andersen MH, "Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration" 13 : 449-459, 2003

18 Liu J, "Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy" 86 : 208-214, 2009

19 Hatanaka H, "Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer" 11 : 815-819, 2000

20 김대근, "Cisplatin의 신장독성에 대한 영지추출물 복합제재의 보호효과" 대한동의병리학회 17 (17): 316-325, 2003

21 Tsang RY, "Cisplatin overdose: toxicities and management" 32 : 1109-1122, 2009

22 Tohamy AA, "Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin" 10 : 45-53, 2003

23 Lasek W, "Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice" 2 : 100-108, 1997

24 Yao D, "Antisense-induced blockade of GATA-3 expression could inhibit Th2 excursion of tumor cells in vitro and in vivo" 2 : 189-196, 2005

25 Yoon TJ, "Anti-tumor metastatic activity of β- glucan purified from mutated Saccharomyces cerevisiae" 8 : 36-42, 2008

26 Lin WW, "A cytokine-mediated link between innate immunity, inflammation, and cancer" 117 : 1175-1183, 2007